Persistence Market Research Blog

Posts tagged ‘Biological Drugs Market’

Global Biological Drugs Market Driven by Favorable Government Policies

Biological drugs are derived from living organisms and are used in the treatment and prevention of chronic illnesses such as auto-immune diseases, blood disorders, cancer, and other medical conditions. Due to the rising prevalence of chronic ailments around the world, coupled with the increasing research and development investments in the healthcare sector, the demand for biological drugs has significantly risen in the recent past. According to a report published by Persistence Market Research, the global biological drugs market, which stood at more US$161 bn in 2014, will reach US$287.1 bn by 2020. If the figures hold true, the market will expand at a robust CAGR of 10.1% between 2015 and 2020.

Favorable Government Policies Aid Market Growth

The market in the last few years has also gained traction from government associations supporting the use of biological drugs. The latest advances introduced in biological science also hold immense potential for the growth of the biological drugs market around the world. Despite witnessing healthy prospects, the high cost of biological drugs and their looming patent expiry may hamper the market’s growth to an extent. Furthermore, the risk of side effects often associated with biological injectable drugs also inhibits the growth of the market.

North America Dominates Global Biological Drugs Market

Regionally, North America dominates the global biological drugs market at present. The region witnesses a high incidence of diabetes, cancer, and other chronic diseases, which subsequently fuels demand from the biological drugs market. Government associations in the region also observe a favorable outlook supporting the use of biological drugs. For instance, the American College of Rheumatology recommended using disease modifying antirheumatic drugs and biologic agents for the treatment of rheumatoid arthritis.

Interested in report: Please follow the below links to meet your requirements; Request for the Report Sample:

Increasing Geriatric Population Boosts Biological Drugs Market in Europe

The biological drugs market in Europe is also growing at a rapid pace due to the increasing geriatric population in the region. According to a report published by the UN, approximately 23.2% of the German population in 2000 was made up of elderly people, and by 2025 the number is expected to reach over 33.2%. Disorders and ailments such as glaucoma and macular degeneration are common among the geriatric population, which fuels demand for biological drugs.

View TOC (table of content), Figures and Tables of the Report:

Leading Enterprises Eyeing to Capitalize on Opportunities in Asia

Enterprises operating in the biological drugs market will also witness lucrative opportunities in Asia. Attracted by the low manufacturing costs incurred in the region, leading biopharmaceutical companies are planning to increase their investment in the region. Lonza, which is a Switzerland-based biotechnology company, has already invested around US$350.0 mn in biological drugs manufacturing in India and Singapore.

For more info:

The global biological drugs market is segmented into monoclonal antibodies (mAb), therapeutic proteins, and vaccines. In terms of therapeutic proteins, the market is segmented into Avonex, Lantus, Enbrel, NovoLog, Neulasta, Aranesp, Victoza, Levemir, Neupogen, Rebif, Humalog, Epogen, Betaseron, and Eylea. Among mAbs, the market is segmented into Remicade, Humira, Avastin, Lucentis Rituxan, and Herceptin. Gardasil, Prevnar 13, Cervarix, Varivax, and Fluzone are the major vaccines in the market.


Global Biological Drugs Market to Reach US$287139.7 Million by 2020 owing to Rising Incidence of Chronic Diseases

New York City, New York, Oct 14, 2015: According to the latest market research report released by Persistence Market Research, the global biological drugs market, which in 2014 stood at US$161056.5 million is anticipated to expand at a CAGR of 10.1% between 2014 and 2020, thereby reaching a market value of US$287139.7 million by 2020. The report titled “Global Market Study on Biological Drugs: North America to Witness Highest Growth By 2020” is available for sale on the company website.

Request Sample Report: (more…)

Global Biological Drugs Market: North America to Witness Highest Growth by 2020

Biological drugs are typically derived from living cells and are used in treatment of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders. Biological drugs have more complex structure than conventional drugs. These are highly sensitive and more difficult to characterize and produce. A biological drug typically has around 250 in-process tests during manufacturing compared to about 50 tests for a conventional drug.

The global market of biological drugs is categorized based on therapeutic protein, mAb and vaccines. The therapeutic protein segmentation is further sub-segmented into Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea.  The mAb segment comprises Humira, Remicade, Rituxan, Avastin, Herceptin and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax and Cervarix.

In terms of geography, North America has the largest market share followed by Europe and Asia in the global biological drugs market. Increased usage of biological drugs for the treatment of diseases, such as cancer, diabetes and other chronic diseases, are supporting the growth of the biological drugs market in the North American region. For instance, in 2012, the American College of Rheumatology, an organization that advances rheumatology through education and research, recommended biologic agents and disease modifying antirheumatic drugs for the treatment of rheumatoid arthritis.

Read complete report at

Tag Cloud